After consecutive years of losses, "abandoned"? Guangxi Wuzhou Zhongheng Group plans to transfer control of Chongqing Lummy Pharmaceutical | Quick Read Announcement.

①Guangxi Wuzhou Zhongheng Group plans to transfer the shares of Chongqing Lummy Pharmaceutical held directly by the company through public solicitation, which may lead to changes in the controlling shareholder and actual controller of the latter. ②The "story" of Guangxi Wuzhou Zhongheng Group's investment in Chongqing Lummy Pharmaceutical began in November 2019, and the following April it became the major shareholder of Chongqing Lummy Pharmaceutical, making Guangxi State-owned Assets Supervision and Administration Commission the actual controller of Chongqing Lummy Pharmaceutical. ③In recent years, Chongqing Lummy Pharmaceutical has been in a continuous state of losses.

cls.cnNov 26 09:55 ET

"Going global" and "innovation" are the key words that cannot be bypassed. Sun Piaoyang from Jiangsu Hengrui Pharmaceuticals, Zhu Yi from Baheal Pharm and other top pharmaceutical industry leaders jointly discuss the next decade | Industry Observation

On November 14, 2024, the opening ceremony of the Insight Conference was held in Chengdu, where experts in the pharmaceutical industry, investors, and chairmen of top listed companies exchanged views on the challenges and opportunities facing the China meheco group. The two key themes of "going global" and "innovation" ran through the entire conference. Faced with the question of the future direction of innovative drugs in China, various enterprises also provided different answers.

cls.cnNov 14 22:16 ET

The hottest summer Artemisia annua is not selling well chongqing taiji industry Q3 performance decreased by 70% | interpretations

In 2024, the national average temperature is the highest for the same period in history since 1961, but the sales volume of Chongqing Taiji Industry Huoxiang Zhengqi Oral Liquid decreased significantly in the third quarter, with a sharp drop in sales of the main product, leading to a year-on-year decline of over 70% in Chongqing Taiji Industry's profit in the third quarter.

cls.cnOct 24 09:59 ET

Jiangsu Hengrui Pharmaceuticals' Q3 revenue was 6.59 billion yuan, with a net income of 1.19 billion yuan, a slight year-on-year increase of 1.9%. | Financial Report Watch

In the third quarter, jiangsu hengrui pharmaceuticals' eps was 0.19 RMB, a year-on-year increase of 5.56%. In the first three quarters, jiangsu hengrui pharmaceuticals' profit increased by 32.98% year-on-year, with eps increasing by 32.73% year-on-year. The main reason is that the company recognized the upfront payment received from Merck Healthcare of 0.16 billion euros as revenue, which significantly increased the profit.

wallstreetcnOct 24 07:58 ET

"Pharmaceuticals king" for financing or listing in Hong Kong? Jiangsu Hengrui Pharmaceuticals has no comment on the rumors.

①There were reports last night that jiangsu hengrui pharmaceuticals is considering a secondary listing in Hong Kong next year, with an expected fundraising amount of 2 billion US dollars. In response, jiangsu hengrui pharmaceuticals stated that they have no comments; ② Industry insiders believe that a secondary listing in Hong Kong can not only raise funds but also enhance the company's international influence.

cls.cnOct 24 01:29 ET

Has the source of funds for the controlling shareholder's shareholding changed? Beijing Balance Medical Technology Co., Ltd. insider: Self-financing can also be done through "special shareholding loans".

①Company insiders have expressed that beijing balance medical technology co., ltd. plans to increase its shareholding through self-raised funds, not ruling out the possibility of increasing company stocks through bank's "stock shareholding special loans". ②Jin Lei, the director of beijing balance medical technology co., ltd., believes that against the backdrop of a sluggish performance in the medical instruments sector, the company's stock price is undervalued by the market.

cls.cnOct 8 21:34 ET